Is RANI or RARE more undervalued in 2026?

CirclFi compares Rani Therapeutics Holdings, Inc (RANI) and Ultragenyx Pharmaceutical Inc. (RARE) using 13 institutional-grade valuation models. RANI has a Quality of Company score of 6.0/10 while RARE scores 6.3/10.

Which is a better buy — RANI or RARE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RANI and RARE valuations compare?

RANI at $0.95 and RARE at $23.26 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RANI vs RARE Valuation Comparison 2026 — Intrinsic Value Analysis

RANI

Biotechnology

Rani Therapeutics Holdings, Inc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.95

Last close

Models

6/13

Active

RARE

Biotechnology

Ultragenyx Pharmaceutical Inc.

Quality

6.3

out of 10

Value Trap

SAFE

Price

$23.26

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RANI Fair Value	RANI Upside	RARE Fair Value	RARE Upside
Bayesian DCF	Intrinsic	$0.20	-79.4%	$7.84	-66.3%
Earnings Power Value	Intrinsic	—	—	$16.16	-32.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.34	-64.3%	$1.44	-93.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RANI vs RARE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RANI vs RARE — Which Stock Is More Undervalued?

RARE scores higher with a 6.3/10 quality rating vs RANI's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rani Therapeutics Holdings, Inc (RANI) and Ultragenyx Pharmaceutical Inc. (RARE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RANI currently trades at $0.95 with a QOC of 6.0/10, while RARE trades at $23.26 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).